An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
A large-scale observation study has been performed to evaluate how tazarotene is used to treat plaque psoriasis in everyday clinical practice and to elucidate whether the efficacy and tolerability of tazarotene treatment can be optimized through the adjunctive use of an emollient and/or a topical corticosteroid. A total of 1393 patients with mild-to-moderate stable plaque psoriasis applied tazarotene 0.05% or 0.1% gel once daily for up to 12 weeks, either as monotherapy or in combination with other topical psoriasis therapies as deemed necessary by the investigator. The adjunctive use of an emollient and/or a corticosteroid enhanced the efficacy of tazarotene treatment and increased the percentage of patients who were satisfied with their treatment. Adjunctive steroid use also enhanced tolerability. The optimal treatment regimen was combination therapy of tazarotene and a corticosteroid.
Tanghetti
E A
EA
Department of Dermatology, University of California at Davis, USA.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004643:Emollients; D005260:Female; D005782:Gels; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D017060:Patient Satisfaction; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome; D012176:Retinoids
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004643:Emollients; D005782:Gels; D005938:Glucocorticoids; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids